[1]
Paoletti, M., Marcellusi, A., Yang, J. and Mennini, F.S. 2023. Cost-effectiveness of IMI/CIL/REL for the treatment of carbapenem non-susceptible Gram-negative bacterial infections. Global and Regional Health Technology Assessment. 10, 1 (Apr. 2023), 18–28. DOI:https://doi.org/10.33393/grhta.2023.2488.